Lv1
60 积分 2025-07-17 加入
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
3天前
已完结
VEGF-A drives TOX-dependent T cell exhaustion in anti–PD-1–resistant microsatellite stable colorectal cancers
12天前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
12天前
已完结
Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer
15天前
已完结
Coffee and Tea Intake, Dementia Risk, and Cognitive Function
18天前
已完结
FGFR rearrangements: oncogenic drivers and therapeutic targets
19天前
已关闭
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
30天前
已完结
Head and Neck Cancer
1个月前
已完结
TROP-2–directed antibody–drug conjugates in advanced NSCLC: A systematic review and meta-analysis of efficacy, safety, and reconstructed survival outcomes
1个月前
已完结
EGFR -mutated non-small cell lung cancer
1个月前
已完结
皖公网安备34019202002308
